![]() |
|
|
Vol. 295, Issue 3, 1022-1030, December 2000
Centro de Neurociências de Coimbra, Universidade de Coimbra
(R.M.V.A., A.J.M.M., D.J.S.L.S.), and Departamento de Engenharia
Biológica e Ambiental, Universidade de Trás-os-Montes e
Alto Douro (D.J.S.L.S), Portugal
The antioxidant effects of carvedilol and its analog BM-910228 (also
known as SB 211475) were studied in rat liver mitochondria as well as
their action on mitochondrial bioenergetics. Carvedilol and BM-910228
inhibited ADP/Fe2+-initiated lipid peroxidation (measured
in mitochondrial membranes as thiobarbituric acid reactive substances
and oxygen consumption) with IC50 values of 10.9 and 0.33 µM, respectively. Under the same conditions, the IC50
value for Trolox C was 18.8 µM. At the same concentration range
showing antioxidant activity both compounds prevent the collapse of
transmembranar electric potential induced by ADP/Fe2+ on
respiring mitochondria. Furthermore, both carvedilol and BM-910228 do
not display toxic effects on mitochondria up to the concentration showing maximal antioxidant effects (
40 µM for carvedilol and
1
µM for BM-910228). At higher concentrations of carvedilol (>40 µM), however, the phosphorylation efficiency of mitochondria is depressed as deduced from a decrease in respiratory control and in the
ADP/oxygen ratio. The Brand approach was used to assess the effects of carvedilol on oxidative phosphorylation. We found that
carvedilol stimulated membrane proton leak and inhibited substrate
oxidation, but had no measurable effect on phosphorylation reactions.
Because carvedilol exerts its antioxidant properties for nontoxic
concentrations, its therapeutic interest is reinforced because it may
potentially prevent mitochondrial dysfunctions associated to cell death
in several pathophysiological states where excessive production of
reactive oxygen species by mitochondria is well documented
(e.g., ischemia/reperfusion). Additionally, its hydroxylated analog
BM-910228 with notable superior antioxidant activity may significantly
contribute to the known therapeutic effects of carvedilol.
This article has been cited by other articles:
![]() |
N. Kalay, E. Basar, I. Ozdogru, O. Er, Y. Cetinkaya, A. Dogan, T. Inanc, A. Oguzhan, N. K. Eryol, R. Topsakal, et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2258 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wang, T. Miura, N. Harada, R. Kametani, M. Shibuya, Y. Fukagawa, S. Kawamura, Y. Ikeda, M. Hara, and M. Matsuzaki Pleiotropic Effects of the beta-Adrenoceptor Blocker Carvedilol on Calcium Regulation during Oxidative Stress-Induced Apoptosis in Cardiomyocytes J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 45 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-W. Chen, F.-Y. Lin, Y.-H. Chen, T.-C. Wu, Y.-L. Chen, and S.-J. Lin Carvedilol Inhibits Tumor Necrosis Factor-{alpha}-Induced Endothelial Transcription Factor Activation, Adhesion Molecule Expression, and Adhesiveness to Human Mononuclear Cells Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2075 - 2081. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kawai, F. Qin, J. Shite, W. Mao, S. Fukuoka, and C.-s. Liang Importance of antioxidant and antiapoptotic effects of {beta}-receptor blockers in heart failure therapy Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1003 - H1012. [Abstract] [Full Text] [PDF] |
||||